Navigation Links
STALLERGENES : Further Profit Growth Acceleration of R&D Expenditure

PARIS, March 12 /PRNewswire-FirstCall/ --

- Further Profit Growth

- Sales up 16% - Profit Before R&D up 19%

- Net Profit (Group Share) up 12%

- Acceleration of R&D Expenditure The Board of Directors, meeting on 11 March 2008 under the chairmanship of Albert Saporta, approved the 2007 consolidated financial statements:

(EUR millions) 2007 As a % 2006 As a % 07/06

of sales of sales % change

Sales 147.1 100.0 126.6 100.0 16

Cost of sales (32.9) (22.3) (29.5) (23.3) 11

Gross profit 114.2 77.7 97.1 76.7 18

General, (65.1) (44.3) (55.9) (44.2) 17

administrative and

sales costs

Profit before R&D 49.1 33.4 41.2 32.5 19

Net R&D expenditure (23.8) (16.2) (18.0) (14.2) 32

Operating profit 25.3 17.2 23.2 18.3 9


Net profit (Group 16.3 11.1 14.6 11.5 12


Diluted earnings per EUR 1.22 EUR 1.11 10


Proposed dividend EUR 0.40 EUR 0.35 14

Net financial debt 10.4 (0.35) 12.0 (0.44) (14)


Accelerated growth in 2007

Growth accelerated in all markets in 2007. The 16% sales increase reflects the vigour of sublingual route, which grew 21%, and its growing awareness among patients. Significant growth in the number of new patients confirmed growing interest in desensitisation for the treatment of allergic diseases.

This excellent sales level generated a 19% increase in profit before R&D, to EUR 49.1 million, and a 9% increase in operating profit (EBIT) to EUR 25.3 million. Net profit (Group share) was EUR 16.3 million, up 12% from the 2006 financial year. These good results must be assessed within the context of a substantial rise in R&D expenditure (up 32%) and sales expenses (up 20%) related to the tablet programme.

A stronger financial position

Net profit margin was maintained at 11.1% and continuing rigorous financial management enabled the Company to generate largely positive free cash flow and reduce net financial debt by 14% to EUR 10.4 million.

ORALAIR(R) Grasses: impending registration of adult and paediatric indications.

The registration of ORALAIR(R) Grasses in Germany should be delivered shortly. The highly positive results of the VO52 paediatric study lead us to expect paediatric extension and a launch in both indications.


- Stallergenes expects further sales growth in 2008 (greater than or equal to 10%).

- The Group is actively preparing the commercial launch of ORALAIR(R) Grasses in Germany and now has an operational industrial platform.

- The laboratory plans to accelerate its R&D effort, which should account for 17% to 18% of sales in 2008, in order to support the current programme and the filing of an IND clinical study application in the US with a view to potential registration in this country.

- Lastly, the Company continues to study partnership proposals for the US.


The Board of Directors will propose to the General Meeting to be held on 30 May 2008, the distribution of a dividend of EUR 0.40 per share, reflecting a 14% increase over the previous year.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitization treatments for the prevention and cure of allergy-related respiratory diseases, e.g. rhino-conjunctivitis, rhinitis and allergic asthma.

A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 16% of its sales to Research and Development and is today fully involved in the development of a new therapeutic family, the sublingual desensitization tablets.

Stallergenes realised 2007 sales of EUR 147 million, of which half outside France.

Stallergenes' shares are listed on Eurolist Compartment B of the Euronext Paris Stock Exchange.

ISIN code: FR0000065674, Reuters code: GEN.PA, Bloomberg code: GEN.FP

For additional information on Stallergenes, please visit our website:

SOURCE Stallergenes
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
2. STALLERGENES and Protein eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens
3. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
4. Stallergenes : 3rd Quarter Sales Up 17%: 9- Month Cumulative Sales Up 17%
5. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
6. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
7. CleveMed Receives $1.5 Million in NIH Funding to Further Develop a Portable System for Monitoring Parkinsons Disease Motor Symptoms
8. SAFC Hitech(TM) Plans Further Expansion Into Asia
9. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
10. Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
11. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
Breaking Biology Technology:
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
Breaking Biology News(10 mins):